Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Author Correction: Circularly permuted and PAM-modified Cas9 variants broaden the targeting scope of base editors.

Huang TP, Zhao KT, Miller SM, Gaudelli NM, Oakes BL, Fellmann C, Savage DF, Liu DR.

Nat Biotechnol. 2019 Jun 10. doi: 10.1038/s41587-019-0168-1. [Epub ahead of print]

PMID:
31182863
2.

Circularly permuted and PAM-modified Cas9 variants broaden the targeting scope of base editors.

Huang TP, Zhao KT, Miller SM, Gaudelli NM, Oakes BL, Fellmann C, Savage DF, Liu DR.

Nat Biotechnol. 2019 Jun;37(6):626-631. doi: 10.1038/s41587-019-0134-y. Epub 2019 May 20. Erratum in: Nat Biotechnol. 2019 Jun 10;:.

PMID:
31110355
3.

Controlling CRISPR-Cas9 with ligand-activated and ligand-deactivated sgRNAs.

Kundert K, Lucas JE, Watters KE, Fellmann C, Ng AH, Heineike BM, Fitzsimmons CM, Oakes BL, Qu J, Prasad N, Rosenberg OS, Savage DF, El-Samad H, Doudna JA, Kortemme T.

Nat Commun. 2019 May 9;10(1):2127. doi: 10.1038/s41467-019-09985-2.

4.

MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival.

Lee CS, Lee LC, Yuan TL, Chakka S, Fellmann C, Lowe SW, Caplen NJ, McCormick F, Luo J.

Proc Natl Acad Sci U S A. 2019 Feb 1. pii: 201817494. doi: 10.1073/pnas.1817494116. [Epub ahead of print]

PMID:
30709910
5.

CRISPR-Cas9 Circular Permutants as Programmable Scaffolds for Genome Modification.

Oakes BL, Fellmann C, Rishi H, Taylor KL, Ren SM, Nadler DC, Yokoo R, Arkin AP, Doudna JA, Savage DF.

Cell. 2019 Jan 10;176(1-2):254-267.e16. doi: 10.1016/j.cell.2018.11.052.

PMID:
30633905
6.

Disruption of the β1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner.

Mancini A, Xavier-Magalhães A, Woods WS, Nguyen KT, Amen AM, Hayes JL, Fellmann C, Gapinske M, McKinney AM, Hong C, Jones LE, Walsh KM, Bell RJA, Doudna JA, Costa BM, Song JS, Perez-Pinera P, Costello JF.

Cancer Cell. 2018 Sep 10;34(3):513-528.e8. doi: 10.1016/j.ccell.2018.08.003.

PMID:
30205050
7.

Systematic discovery of natural CRISPR-Cas12a inhibitors.

Watters KE, Fellmann C, Bai HB, Ren SM, Doudna JA.

Science. 2018 Oct 12;362(6411):236-239. doi: 10.1126/science.aau5138. Epub 2018 Sep 6.

8.

Extension of the crRNA enhances Cpf1 gene editing in vitro and in vivo.

Park HM, Liu H, Wu J, Chong A, Mackley V, Fellmann C, Rao A, Jiang F, Chu H, Murthy N, Lee K.

Nat Commun. 2018 Aug 17;9(1):3313. doi: 10.1038/s41467-018-05641-3.

9.

Differential Effector Engagement by Oncogenic KRAS.

Yuan TL, Amzallag A, Bagni R, Yi M, Afghani S, Burgan W, Fer N, Strathern LA, Powell K, Smith B, Waters AM, Drubin D, Thomson T, Liao R, Greninger P, Stein GT, Murchie E, Cortez E, Egan RK, Procter L, Bess M, Cheng KT, Lee CS, Lee LC, Fellmann C, Stephens R, Luo J, Lowe SW, Benes CH, McCormick F.

Cell Rep. 2018 Feb 13;22(7):1889-1902. doi: 10.1016/j.celrep.2018.01.051.

10.

Prediction of potent shRNAs with a sequential classification algorithm.

Pelossof R, Fairchild L, Huang CH, Widmer C, Sreedharan VT, Sinha N, Lai DY, Guan Y, Premsrirut PK, Tschaharganeh DF, Hoffmann T, Thapar V, Xiang Q, Garippa RJ, Rätsch G, Zuber J, Lowe SW, Leslie CS, Fellmann C.

Nat Biotechnol. 2017 Apr;35(4):350-353. doi: 10.1038/nbt.3807. Epub 2017 Mar 6.

11.

Cornerstones of CRISPR-Cas in drug discovery and therapy.

Fellmann C, Gowen BG, Lin PC, Doudna JA, Corn JE.

Nat Rev Drug Discov. 2017 Feb;16(2):89-100. doi: 10.1038/nrd.2016.238. Epub 2016 Dec 23. Review.

12.

Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch.

Oakes BL, Nadler DC, Flamholz A, Fellmann C, Staahl BT, Doudna JA, Savage DF.

Nat Biotechnol. 2016 Jun;34(6):646-51. doi: 10.1038/nbt.3528. Epub 2016 May 2.

13.

Tail function during arboreal quadrupedalism in squirrel monkeys (Saimiri boliviensis) and tamarins (Saguinus oedipus).

Young JW, Russo GA, Fellmann CD, Thatikunta MA, Chadwell BA.

J Exp Zool A Ecol Genet Physiol. 2015 Oct;323(8):556-66. doi: 10.1002/jez.1948. Epub 2015 Jul 14.

PMID:
26173756
14.

MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.

Nowak DG, Cho H, Herzka T, Watrud K, DeMarco DV, Wang VM, Senturk S, Fellmann C, Ding D, Beinortas T, Kleinman D, Chen M, Sordella R, Wilkinson JE, Castillo-Martin M, Cordon-Cardo C, Robinson BD, Trotman LC.

Cancer Discov. 2015 Jun;5(6):636-51. doi: 10.1158/2159-8290.CD-14-1113. Epub 2015 Mar 31.

15.

A computational algorithm to predict shRNA potency.

Knott SRV, Maceli A, Erard N, Chang K, Marran K, Zhou X, Gordon A, Demerdash OE, Wagenblast E, Kim S, Fellmann C, Hannon GJ.

Mol Cell. 2014 Dec 18;56(6):796-807. doi: 10.1016/j.molcel.2014.10.025. Epub 2014 Nov 26.

16.

Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma.

Robert F, Roman W, Bramoullé A, Fellmann C, Roulston A, Shustik C, Porco JA Jr, Shore GC, Sebag M, Pelletier J.

Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13421-6. doi: 10.1073/pnas.1402650111. Epub 2014 Sep 2.

17.

Development of siRNA payloads to target KRAS-mutant cancer.

Yuan TL, Fellmann C, Lee CS, Ritchie CD, Thapar V, Lee LC, Hsu DJ, Grace D, Carver JO, Zuber J, Luo J, McCormick F, Lowe SW.

Cancer Discov. 2014 Oct;4(10):1182-1197. doi: 10.1158/2159-8290.CD-13-0900. Epub 2014 Aug 6.

18.

Limb bone morphology, bone strength, and cursoriality in lagomorphs.

Young JW, Danczak R, Russo GA, Fellmann CD.

J Anat. 2014 Oct;225(4):403-18. doi: 10.1111/joa.12220. Epub 2014 Jul 21.

19.

Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.

Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Gadal S, Saborowski M, Kastenhuber E, Fellmann C, Ohara K, Morikami K, Miura T, Lukacs C, Ishii N, Lowe S, Rosen N.

Cancer Cell. 2014 May 12;25(5):697-710. doi: 10.1016/j.ccr.2014.03.011. Epub 2014 Apr 17.

20.

Stable RNA interference rules for silencing.

Fellmann C, Lowe SW.

Nat Cell Biol. 2014 Jan;16(1):10-8. doi: 10.1038/ncb2895. Review.

21.

An optimized microRNA backbone for effective single-copy RNAi.

Fellmann C, Hoffmann T, Sridhar V, Hopfgartner B, Muhar M, Roth M, Lai DY, Barbosa IA, Kwon JS, Guan Y, Sinha N, Zuber J.

Cell Rep. 2013 Dec 26;5(6):1704-13. doi: 10.1016/j.celrep.2013.11.020. Epub 2013 Dec 12.

22.

A pipeline for the generation of shRNA transgenic mice.

Dow LE, Premsrirut PK, Zuber J, Fellmann C, McJunkin K, Miething C, Park Y, Dickins RA, Hannon GJ, Lowe SW.

Nat Protoc. 2012 Feb 2;7(2):374-93. doi: 10.1038/nprot.2011.446.

23.

Tiling genomes of pathogenic viruses identifies potent antiviral shRNAs and reveals a role for secondary structure in shRNA efficacy.

Tan X, Lu ZJ, Gao G, Xu Q, Hu L, Fellmann C, Li MZ, Qu H, Lowe SW, Hannon GJ, Elledge SJ.

Proc Natl Acad Sci U S A. 2012 Jan 17;109(3):869-74. doi: 10.1073/pnas.1119873109. Epub 2012 Jan 4.

24.

An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance.

Zuber J, Rappaport AR, Luo W, Wang E, Chen C, Vaseva AV, Shi J, Weissmueller S, Fellmann C, Taylor MJ, Weissenboeck M, Graeber TG, Kogan SC, Vakoc CR, Lowe SW.

Genes Dev. 2011 Aug 1;25(15):1628-40. doi: 10.1101/gad.17269211. Erratum in: Genes Dev. 2011 Sep 15;25(18):1997. Fellman, Christof [corrected to Fellmann, Christof].

25.

Functional identification of optimized RNAi triggers using a massively parallel sensor assay.

Fellmann C, Zuber J, McJunkin K, Chang K, Malone CD, Dickins RA, Xu Q, Hengartner MO, Elledge SJ, Hannon GJ, Lowe SW.

Mol Cell. 2011 Mar 18;41(6):733-46. doi: 10.1016/j.molcel.2011.02.008. Epub 2011 Feb 25.

26.

Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi.

Zuber J, McJunkin K, Fellmann C, Dow LE, Taylor MJ, Hannon GJ, Lowe SW.

Nat Biotechnol. 2011 Jan;29(1):79-83. doi: 10.1038/nbt.1720. Epub 2010 Dec 5.

27.

HIF-1 antagonizes p53-mediated apoptosis through a secreted neuronal tyrosinase.

Sendoel A, Kohler I, Fellmann C, Lowe SW, Hengartner MO.

Nature. 2010 Jun 3;465(7298):577-83. doi: 10.1038/nature09141.

28.

The Panomat P-10 micro-volumetric infusion pump is suitable for continuous drug administration at minimal flow rates.

Neff TA, Fellmann C, Fuechslin RM, Gerber AC, Weiss M.

Can J Anaesth. 2002 Dec;49(10):1048-52.

PMID:
12477676
29.

Apnoea in a former preterm infant after caudal bupivacaine with clonidine for inguinal herniorrhaphy.

Fellmann C, Gerber AC, Weiss M.

Paediatr Anaesth. 2002 Sep;12(7):637-40.

PMID:
12358663
30.

Response force titration for the assessment of the neuromuscular toxicity of 2,5-hexanedione in rats.

Elsner J, Fellmann C, Zbinden G.

Neurotoxicol Teratol. 1988 Jan-Feb;10(1):3-13.

PMID:
3352566

Supplemental Content

Loading ...
Support Center